PharmaCyte Biotech’s Contract Research Organization Voted Australia’s Favorite CRO for 2015
June 09 2015 - 9:25AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today reported that Clinical Network
Services (CNS), the Contract Research Organization (CRO) chosen by
PharmaCyte Biotech to prepare for and conduct its upcoming Phase 2b
clinical trial in pancreatic cancer, has been voted Australia’s
favorite CRO for 2015.
The award was presented to CNS at the 2015 ARCS
Scientific Congress and was based on votes from local
investigational study sites and from local and international
sponsors of clinical trials. ARCS Australia Ltd., previously known
as the Association of Regulatory and Clinical Scientists, is a
professional development organization for those working in the
development of disease therapies.
Gabrielle McKee, CNS’ Chief Operating Officer,
said of the award, “CNS is proud and honored to have won this
award. As a company, CNS has always been committed to maintaining a
positive culture focused on how we interact with each other, our
clients and importantly the wonderful clinicians, coordinators and
pharmacists who are at the forefront of delivering our trials to
patients.”
PharmaCyte Biotech’s Chief Executive Officer,
Kenneth L. Waggoner, offered the company’s congratulations,
stating, “All of us at PharmaCyte Biotech would like to offer our
sincerest congratulations to those at CNS in winning the ARCS award
as Australia’s Favorite CRO for 2015. When we were evaluating CRO’s
that might best assist us in our Phase 2b clinical trial in those
with advanced pancreatic cancer in Australia, it became evident
early on in that process that CNS was one of Australia’s leading
CROs.”
“This evaluation has been proven correct by the
excellent and most professional manner in which CNS’ personnel have
interacted with us since our contracts with CNS were signed. The
ARCS award to CNS bolters our already high confidence that CNS will
prove to be a valuable partner as we develop our treatment for one
of the deadliest cancers.”
Russell Neal, Managing Director of CNS,
commented, “It has been an exciting year or so for all of us at
CNS, and to this receive recognition from ARCS is testament to the
exceptional hard work and commitment everyone at CNS brings to our
client’s programs. We’re very proud of our growing reputation as it
presents us with opportunities to work with cutting edge
technologies, such as PharmaCyte Biotech’s exciting Cell-in-a-Box®
and their wonderfully talented team.”
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company focused on developing and
preparing to commercialize treatments for cancer and diabetes based
upon a proprietary cellulose-based live cell encapsulation
technology known as Cell-in-a-Box®. This unique and patented
technology will be used as a platform upon which treatments for
several types of cancer, including advanced, inoperable pancreatic
cancer, and diabetes are being built. PharmaCyte Biotech's
treatment for pancreatic cancer involves low doses of the
well-known anticancer prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. These capsules are placed as close to the
cancerous tumor as possible to enable the delivery of the highest
levels of the cancer-killing drug at the source of the cancer. This
"targeted chemotherapy" has proven remarkably effective in past
clinical trials.
In addition, PharmaCyte Biotech is working towards improving the
quality of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors.
PharmaCyte Biotech is also developing treatments
for cancer based upon chemical constituents of the Cannabis plant,
known as cannabinoids. In doing so, PharmaCyte Biotech is examining
ways to exploit the benefits of Cell-in-a-Box® technology in
optimizing the anticancer effectiveness of cannabinoids, while
minimizing or outright eliminating the debilitating side effects
usually associated with cancer treatments. This provides PharmaCyte
Biotech the rare opportunity to develop “green” approaches to
fighting deadly diseases, such as cancer of the pancreas, brain and
breast, which affect hundreds of thousands of individuals worldwide
every year.
Safe HarborThis press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com